研究文章
模式的转移性雌激素受体阳性乳腺癌的进展:一个论点为当地治疗
|
|
整个队列 |
扩散的进展 |
有限的进展(< 3网站) |
| 整个队列 |
Oligoprogression |
Oligometastatic +进展 |
|
| 患者中, |
108年 |
74年 |
34 |
23 |
11 |
|
| 诊断,年龄中位数(范围) |
55(22 - 82)年 |
54(22 - 80)年 |
57(26 - 82)年 |
59(39 - 82)年 |
52(26 - 76)年 |
| 年龄大都会 |
55(22 - 84)年 |
55(22 - 84)年 |
59(28 - 82)年 |
60(41 - 82)年 |
55(28 - 76)年 |
|
| 表型,(%) |
|
|
|
|
|
| ER (+) / PR (+) / Her2 (−) |
73例(68%) |
54 (73%) |
19 (56%) |
17 (74%) |
2 (18%) |
| ER(+) /公关(−)/ Her2 (−) |
14 (13%) |
8 (11%) |
6 (18%) |
3 (13%) |
3 (27%) |
| ER (+) / PR (+) / Her2 (+) |
12 (11%) |
7 (9%) |
5 (15%) |
1 (4%) |
4 (36%) |
| ER(+) /公关(−)/ Her2 (+) |
9 (8%) |
5 (7%) |
4 (12%) |
2 (9%) |
2 (18%) |
|
| 时间转移 |
|
|
|
|
|
| 中位数(范围) |
1(0 - 99)个月 |
1(0 - 99)个月 |
10(0-49)个月 |
4(0-49)个月 |
10(0 30)个月 |
| 从最初的Dx≤6个月,(%) |
63例(58%) |
46 (62%) |
17 (50%) |
13 (57%) |
4 (36%) |
| > 6个月从最初的Dx,(%) |
45 (42%) |
28 (38%) |
17 (50%) |
10 (43%) |
7 (64%) |
|
| 转移的程度,(%) |
|
|
|
|
|
| ≤6网站的疾病 |
30 (28%) |
15 (20%) |
15 (44%) |
4 (17%) |
11 (100%) |
| > 6网站的疾病 |
78例(72%) |
52 (70%) |
19 (56%) |
19 (83%) |
0 (0%) |
|
| 疾病的网站,(%) |
|
|
|
|
|
| 骨 |
69例(64%) |
53 (72%) |
16 (47%) |
12 (52%) |
4 (36%) |
| 地方/区域 |
42 (39%) |
34 (46%) |
7 (21%) |
4 (17%) |
3 (27%) |
| 肺、纵隔 |
37 (34% |
27 (36%) |
10 (29%) |
9 (39%) |
1 (9%) |
| 肝 |
34 (31%) |
22 (30%) |
12 (35%) |
8 (35%) |
4 (36%) |
| 大脑 |
4 (4%) |
3 (4%) |
1 (3%) |
1 (4%) |
0 (0%) |
| 其他 |
9 (8%) |
7 (9%) |
2 (6%) |
2 (9%) |
0 (0%) |
|
| 化疗之前,(%) |
45 (42%) |
24 (32%) |
17 (50%) |
11 (48%) |
6 (55%) |
| 内分泌治疗之前,(%) |
44 (41%) |
28 (38%) |
16 (47%) |
10 (43%) |
6 (55%) |
|
| 轮内分泌治疗,(%) |
|
|
|
|
|
| 1 |
57 (53%) |
47 (64%) |
10 (29%) |
5 (22%) |
5 (45%) |
| 2 |
18 (17%) |
8 (11%) |
10 (29%) |
8 (35%) |
2 (18%) |
| 3 |
29 (27%) |
17 (23%) |
12 (35%) |
9 (39%) |
3 (27%) |
| 4 |
4 (4%) |
2 (3%) |
2 (6%) |
1 (4%) |
1 (9%) |
|
|
呃:雌激素受体;公关:孕激素受体;Her2: Her2neu。
|
